Guangzhou Tosun Pharmaceutical Co., Ltd.

Primary objective: This study uses rupatadine fumarate tablets developed by Guangzhou Tonghui Pharmaceutical Co., Ltd. (manufacturer: Hubei Weisen Pharmaceutical Co., Ltd., specification: 10 mg) as the test preparation and rupatadine fumarate tablets (trade name: Rupafin, specification: 10 mg), a non-imported original drug of the original research unit Laboratorios ERN, S.A., as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under fasting or postprandial conditions. Secondary objective: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary Objective: This study used olopatadine hydrochloride granules (2.5 mg) provided by Guangzhou Tonghui Pharmaceutical Co., Ltd. as the test formulation and olopatadine hydrochloride granules (trade name: Allelock, 0.5% (2.5 mg/0.5 g)) manufactured by Kyowa Kirin Co., Ltd. as the reference formulation. The pharmacokinetic parameters of the test and reference formulations in healthy participants under fasting and postprandial conditions were investigated to evaluate their bioequivalence. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.